RE:Does anyone have a extra idea for our retail IR list?Good summary, to which I might add:
Upcoming Interim patient enrolment and another potentail Baxter milestone payment/cash infusion. Anticipated Interim patient enrollment (60%) Q2 or Q3 of 2021.
Tigris is an Open Label, confirmatory Trial. What happens if Dr's like what they see as far as results? Also anticpated results from separate PMX/Covid Study.
Although PMX may not be an effective treatment against Covid pe se, Covid seems to be increasing the incidence of Severe Sepsis and AKI, both of which could increase the TAM (total available market) for Spectral products.
PMA path taken gives Spectral 7-10 years of market exclusivity in the US if FDA approved. 2020 saw the confirmation of the extension of the Toray exclusive license for US and Canada to 2034 and beyond.
No other large sponsored Sepsis Trials in the US currently (including from supposed competition/players like CTSO and SIGY)
DIMI adn SAMI is considered to be "disruptive technology" in the CRRT and HHD world, in large part due to reduced complexity, ease of training, communicative features, etc.
Limited compettion in the world of HHD machines. Two other players have received valuations approaching $ 2B... in recognition of this rapidly expanding market and huge potential for future growth. Also suggests Spectral is not a one-trick pony (i.e all about PMX). i.e it's derisked not only by Baxter participation, but by the fact that it seems to be developing very competitive CRRT and HHD equipment.